会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 90. 发明公开
    • FLT3 RECEPTOR INHIBITOR AT LOW DOSAGE FOR THE TREATMENT OF NEUROPATHIC PAIN
    • FLT3受体抑制剂在低剂量治疗神经性疼痛中的应用
    • EP3254698A1
    • 2017-12-13
    • EP16305669.0
    • 2016-06-08
    • UNIVERSITE DE MONTPELLIERAxLR SATT DU LANGUEDOC ROUSSILLON (SATT AXLR)INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    • VALMIER, Jean
    • A61K45/00A61P23/00
    • A61K45/00
    • The present invention relates to FLT3 receptor inhibitor for use in the treatment of neuropathic pain and chronic pain comprising a neuropathic component, wherein the daily dosage range per human adult per day of said FLT3 receptor inhibitor consists of a dosage range determined by a method comprising the steps of:
      - (i) determining the minimal inhibiting dose of said FLT3 receptor inhibitor that induces the maximal inhibition of mechanical pain hypersensitivity,
      - (ii) converting said dose to the Human Equivalent Dose (HED) by the allometric correction method, , and
      - (iii) establishing a daily dosage range per human adult per day wherein
      (iii-1) the lower limit of the said daily dosage range per human adult per day is the greater value between HED/20 determined via a rat model and 0.001 mg, and
      (iii-2) the upper limit of the said daily dosage range is the lower value between HED*20 determined via a rat model and 50 mg.
    • 本发明涉及用于治疗神经性疼痛和慢性疼痛的FLT3受体抑制剂,其包含神经性成分,其中所述FLT3受体抑制剂每人每日成人的日剂量范围由通过包含 (i)确定诱导机械性疼痛超敏反应的最大抑制的所述FLT3受体抑制剂的最小抑制剂量,(ii)通过异星校正方法将所述剂量转化为人类等效剂量(HED),和 - (iii)建立每人每天成人日剂量范围,其中(iii-1)每人每天成人日剂量范围的下限是通过大鼠模型确定的HED / 20与0.001mg ,和(iii-2)所述日剂量范围的上限是经由大鼠模型确定的HED * 20与50mg之间的较低值。